Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) – Drugs In Development, 2024 report and make more profitable business decisions.
Adrenoleukodystrophy is a disorder that occurs most often in males. It mainly affects the nervous system and the adrenal glands, which are small glands located on top of each kidney. Abetalipoproteinemia is also a kind of adrenoleukodystrophy (adrenomyeloneuropathy/Schilder-Addison complex). Bassen-Kornzweig syndrome is a rare disease passed down through families in which a person is unable to fully absorb dietary fats through the intestines. The disease is caused by a defect in the gene that tells the body to create lipoproteins. Symptoms include curvature of the spine, muscle weakness, and decrease of vision over time. Treatment involves large doses of vitamin supplements containing fat-soluble vitamins.
The Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) drugs in development market research report provide comprehensive information on the therapeutics under development for Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 20 molecules, with 15 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Apteeus SASAutobahn Therapeutics Inc
Celularity Inc
Centers of Biomedical Research Network
Consortium Center for Biomedical Research Network
Duke University
Imstem Biotechnology Inc
MedDay SA
Minoryx Therapeutics sl
Orpheris Inc
Poxel SA
ReceptoPharm Inc
Scenic Biotech BV
Shenzhen Geno-Immune Medical Institute
Shenzhen Second People's Hospital
SwanBio Therapeutics Inc
Vigil Neuroscience Inc
Viking Therapeutics Inc
Table of Contents
Table
Figures
Frequently asked questions